These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27769592)

  • 1. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.
    Tarp S; Furst DE; Dossing A; Østergaard M; Lorenzen T; Hansen MS; Singh JA; Choy EH; Boers M; Suarez-Almazor ME; Kristensen LE; Bliddal H; Christensen R
    Semin Arthritis Rheum; 2017 Jun; 46(6):699-708. PubMed ID: 27769592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.
    Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe DJ; Bombardier C
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010227. PubMed ID: 27571502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.
    Buckley F; Finckh A; Huizinga TW; Dejonckheere F; Jansen JP
    J Manag Care Spec Pharm; 2015 May; 21(5):409-23. PubMed ID: 25943002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis.
    Albert DA
    J Clin Rheumatol; 2015 Dec; 21(8):398-404. PubMed ID: 26226612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.
    Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe D; Bombardier C
    BMJ; 2016 Apr; 353():i1777. PubMed ID: 27102806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP; Buckley F; Dejonckheere F; Ogale S
    Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.
    Camean-Castillo M; Gimeno-Ballester V; Rios-Sanchez E; Fenix-Caballero S; Vázquez-Real M; Alegre-Del Rey E
    J Clin Pharm Ther; 2019 Jun; 44(3):384-396. PubMed ID: 30729557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept for the treatment of rheumatoid arthritis.
    Lethaby A; Lopez-Olivo MA; Maxwell L; Burls A; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD004525. PubMed ID: 23728649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.
    Alfonso-Cristancho R; Armstrong N; Arjunji R; Riemsma R; Worthy G; Ganguly R; Kleijnen J
    Clin Rheumatol; 2017 Jan; 36(1):25-34. PubMed ID: 27726046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials.
    Tarp S; Jørgensen TS; Furst DE; Dossing A; Taylor PC; Choy EH; Suarez-Almazor ME; Lyddiatt A; Kristensen LE; Bliddal H; Christensen R
    Semin Arthritis Rheum; 2019 Jun; 48(6):958-966. PubMed ID: 30396592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
    Tarp S; Eric Furst D; Boers M; Luta G; Bliddal H; Tarp U; Heller Asmussen K; Brock B; Dossing A; Schjødt Jørgensen T; Thirstrup S; Christensen R
    Rheumatology (Oxford); 2017 Mar; 56(3):417-425. PubMed ID: 28013201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect comparison of biological treatments in refractory rheumatoid arthritis.
    Gallego-Galisteo M; Villa-Rubio A; Alegre-del Rey E; Márquez-Fernández E; Ramos-Báez JJ
    J Clin Pharm Ther; 2012 Jun; 37(3):301-7. PubMed ID: 21831256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis.
    Turkstra E; Ng SK; Scuffham PA
    Curr Med Res Opin; 2011 Oct; 27(10):1885-97. PubMed ID: 21848493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
    CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.